Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ionis, Bayer deal

Ionis will receive a $75 million milestone payment from Bayer tied the development of anticoagulants

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE